Coral Connect Acquires AdvisorWoRx to Tackle Infusion Care's Execution Gap

CORAL SPRINGS, FL – July 06, 2026 – In a strategic move poised to reshape the operational backbone of specialty infusion, Coral Connect announced today its acquisition of AdvisorWoRx, a highly regarded healthcare consulting firm. The deal brings not just a portfolio of expertise but also a formidable leader, as AdvisorWoRx founder Edie Gigot, MSN-RN, MBA, steps into the newly created role of President of Infusion Services at Coral.

The acquisition signals a significant consolidation play within the burgeoning specialty infusion sector, a market estimated at over $100 billion annually. Coral Connect, a technology and services platform backed by private equity firm Windrose Health Investors, aims to integrate AdvisorWoRx’s deep operational consulting into its own data-driven enablement platform. The goal is to solve what Coral's CEO, Jeremy Moskow, bluntly calls the industry's "execution problem," a complex web of inefficiencies that often leaves patients waiting for critical therapies.

A Calculated Move in a Fragmented Market

The specialty infusion market is characterized by powerful tailwinds and profound fragmentation. An aging population, the rising prevalence of chronic diseases, and a pipeline of new specialty drugs—nearly 80% of which require infusion—are driving a projected growth rate of 6-10% annually. This growth is increasingly happening outside of expensive hospital settings, in more cost-effective ambulatory infusion centers (AICs) and patient homes.

However, the provider landscape is fractured. While giants like Option Care Health, OptumRx, and CVS's Coram hold a combined market share of roughly 50%, the other half is composed of a vast number of smaller, independent providers. This fragmentation creates operational challenges but also presents a significant opportunity for consolidation and optimization, a fact not lost on private equity.

Windrose Health Investors, Coral Connect's backer, has a history of investing in tech-enabled platforms that drive efficiency in resource-strained healthcare sectors. This acquisition fits squarely within that strategy. By absorbing AdvisorWoRx, Coral isn't just buying a company; it's acquiring a proven methodology for untangling the clinical and administrative knots that plague infusion providers. The move strengthens its position as an essential "enablement platform"—an orchestration layer that helps the disparate players in the market operate more effectively. Instead of competing directly with every provider, Coral aims to become the indispensable partner that helps them all "buy smarter, run leaner and collect more."

The Architect of Execution

At the heart of this strategy is Edie Gigot, a leader whose career has been forged in the very operational realities the acquisition seeks to address. A nurse by training, Gigot possesses what the company calls a "rare end-to-end view of specialty infusion." Her experience spans leadership roles at some of the industry's most recognized names, including running clinical operations for home infusion providers AxelaCare and ARJ Infusion Services, and serving as Senior Vice President of Specialty Pharmacy for the rapidly growing FlexCare Infusion Centers.

Perhaps most notably, Gigot was the driving force behind the National Infusion Center Association (NICA)’s Standards of Excellence. As Accreditation Program Director, she led the development of the quality and safety framework that has become the benchmark for the entire non-hospital infusion segment. This work filled a critical void, creating a standardized measure of excellence for a rapidly expanding, yet loosely regulated, part of healthcare.

“Specialty infusion does not have a knowledge problem. It has an execution problem," said Jeremy Moskow, Chief Executive Officer of Coral. "Edie has spent her career inside the operating reality of this industry. She has run nursing and pharmacy teams, built specialty pharmacy operations, and written the accreditation standards the industry measures itself against. There is no one better positioned to lead how Coral builds, staffs, and runs infusion services for our customers.”

From Silos to Integrated Solutions

Gigot herself identifies the central challenge: operational silos. "Every infusion operator I have worked with faces the same structural reality," she stated. "Clinical decisions, procurement decisions, and reimbursement decisions are made in separate silos, and patients wait while the silos reconcile."

A patient requiring a specialty biologic, for example, might be caught in a frustrating loop. The clinical team determines the need, the procurement team sources the high-cost drug based on purchasing agreements, and the revenue cycle team navigates the complex prior authorization and billing requirements. When these departments operate independently, using different systems and priorities, the result is often delays, administrative waste, and a fragmented patient experience.

The integration of AdvisorWoRx into Coral Connect is designed to tear down these walls. AdvisorWoRx’s expertise in workflow optimization, accreditation readiness, and clinical compliance will no longer be a one-off consulting engagement. Instead, it will be embedded directly into Coral’s technology platform and managed services. This creates a unified system where clinical protocols can inform procurement, and reimbursement data can provide real-time feedback to both. The mission, as Gigot puts it, is simple: "Get patients on therapy faster."

This combined services-and-technology model is also attractive from a business perspective. While terms of the deal were not disclosed, healthcare consulting firms with specialized expertise and recurring revenue potential often command premium valuations. By integrating advisory services into a scalable tech platform, Coral is creating a powerful, high-value offering for its health system, AIC, and specialty pharmacy clients. As President of Infusion Services, Gigot will now oversee this entire integrated ecosystem, from health system dispensing programs to pharmacy management and clinical quality infrastructure. All existing AdvisorWoRx engagements will transition seamlessly to Coral, ensuring continuity for clients while scaling the impact of Gigot's team across a national network.

This acquisition is more than a line item on a balance sheet; it is a declaration of intent. Coral Connect is betting that the key to unlocking value in the complex world of specialty infusion lies not in owning the clinics, but in mastering the process. By bringing in the architect of operational execution, the company is positioning itself to build the integrated infrastructure the industry has been waiting for.